FDA won't hold companies responsible for independent user content on their social media properties

U.S. pharmaceutical companies may have gotten off easy compared to other areas of the world, said Peter Pitts, president of the Center for Medicine in the Public Interest and a former associate commissioner at the FDA.

The European Court of Justice recently ruled that online remarks about drugs posted by a third party on the manufacturer's Web property could constitute advertising, even though the post's author has no connection with the product's manufacturer or marketer.

“That's carte blanche for an almost complete gag order on anyone who wants to discuss anything to do with medicines,” Pitts said.
Sign Up for Our Email Newsletter

RECENT NEWS

Sorry, but the ‘drugs from Canada’ don’t work

Sorry, but the ‘drugs from Canada’ don’t work

“Drugs from Canada” is a policy that won’t work. And a political soundbite that won’t die....  Read more

Product Failure Is Not Process Failure

Product Failure Is Not Process Failure

FDA be nimble. FDA be quick. FDA jump over the bureaucratic schtick....  Read more

The Future of U.S. Biopharmaceutical Innovation and Supply Chain Security Lies in the Abraham Accords Region

The Future of U.S. Biopharmaceutical Innovation and Supply Chain Security Lies in the Abraham Accords Region

Congress must enact legislation that pushes our country forward, builds bridges where there are gaps, and leverages strat...  Read more

DRUGWONKS BLOG